Society of Nuclear Medicine Offers Online CME

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

RESTON, Virginia-The Society of Nuclear Medicine (SNM) has formed an online collaboration with Medscape, a website for health care professionals and consumers, to release an educational program highlighting key content from the SNM’s 2001 annual conference.

RESTON, Virginia—The Society of Nuclear Medicine (SNM) has formed an online collaboration with Medscape, a website for health care professionals and consumers, to release an educational program highlighting key content from the SNM’s 2001 annual conference.

This free CME program, available on Medscape (www.medscape.com), showcases scientific articles covering core topics of interest to nuclear medicine specialists and specialty physicians. The program has been approved for 2 Category 1 CME credits by the SNM.

In a separate news release, the Society announced that webcasts of sessions from the annual conference are available in the SNM Virtual Library, produced by DigiScript. The cost, including CME credits, is $25 for members and $40 for nonmembers. To subscribe, go to www.snm.org

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.